# ![@Prof_Dollar Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::3015098824.png) @Prof_Dollar Prof. Dollar

Prof. Dollar posts on X about $qure, $phar, strong, science the most. They currently have [-----] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours.

### Engagements: [-----] [#](/creator/twitter::3015098824/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::3015098824/c:line/m:interactions.svg)

- [--] Week [------] +9.50%
- [--] Month [------] -17%
- [--] Months [-------] +458%
- [--] Year [-------] +633%

### Mentions: [--] [#](/creator/twitter::3015098824/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::3015098824/c:line/m:posts_active.svg)

- [--] Month [--] -41%
- [--] Months [---] +300%
- [--] Year [---] +396%

### Followers: [-----] [#](/creator/twitter::3015098824/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::3015098824/c:line/m:followers.svg)

- [--] Week [-----] +0.19%
- [--] Month [-----] +1.20%
- [--] Months [-----] +49%
- [--] Year [-----] +59%

### CreatorRank: [-------] [#](/creator/twitter::3015098824/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::3015098824/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[finance](/list/finance)  100% [stocks](/list/stocks)  11% [cryptocurrencies](/list/cryptocurrencies)  2% [celebrities](/list/celebrities)  1% [countries](/list/countries)  1% [travel destinations](/list/travel-destinations)  1% [social networks](/list/social-networks)  1% [technology brands](/list/technology-brands)  1%

**Social topic influence**
[$qure](/topic/$qure) #4, [$phar](/topic/$phar) 8%, [strong](/topic/strong) 8%, [science](/topic/science) 6%, [acquisition](/topic/acquisition) 4%, [$clpt](/topic/$clpt) 4%, [$xbi](/topic/$xbi) 4%, [staff](/topic/staff) 3%, [$sgmo](/topic/$sgmo) 3%, [the first](/topic/the-first) 3%

**Top accounts mentioned or mentioned by**
[@fda](/creator/undefined) [@4drant](/creator/undefined) [@pawcio2009](/creator/undefined) [@desertdweller93](/creator/undefined) [@canoebrookbl](/creator/undefined) [@amaymd](/creator/undefined) [@uniqurenv](/creator/undefined) [@zinselmeyerb](/creator/undefined) [@drmakaryfda](/creator/undefined) [@srqstockpicker](/creator/undefined) [@biotechai](/creator/undefined) [@biotechanalysst](/creator/undefined) [@vprasadmdmph](/creator/undefined) [@angierasmussen](/creator/undefined) [@davidaxelrod](/creator/undefined) [@seedy19tron](/creator/undefined) [@jlucer53](/creator/undefined) [@kumodongli](/creator/undefined) [@clearpath100](/creator/undefined) [@appalachiangabe](/creator/undefined)

**Top assets mentioned**
[uniQure N.V. (QURE)](/topic/$qure) [Pharming Group N.V. (PHAR)](/topic/$phar) [Bluefin (BLUE)](/topic/$blue) [NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)](/topic/$nams) [Merus N.V. Common Shares (MRUS)](/topic/$mrus) [Amgen, Inc. (AMGN)](/topic/$amgn) [Decibel Therapeutics, Inc. (DBTX)](/topic/$dbtx) [BioMarin Pharmaceutical, Inc. (BMRN)](/topic/$bmrn) [Clipper Realty Inc. Common Stock (CLPR)](/topic/$clpr) [Pfizer, Inc. (PFE)](/topic/$pfe) [Biohaven Pharmaceutical Holding Company Ltd. (BHVN)](/topic/$bhvn) [Sarepta Therapeutics, Inc. (SRPT)](/topic/$srpt) [Arrowhead Research Corporation (ARWR)](/topic/$arwr)
### Top Social Posts
Top posts by engagements in the last [--] hours

"$PHAR The FDA issued a Complete Response Letter for the pediatric sNDA of #Joenja (leniolisib) requesting additional pediatric pharmacokinetic data to confirm dosing in lower-weight children as well as clarification on a batch testing method. Press: https://www.pharming.com/nl/node/575 https://www.pharming.com/nl/node/575"  
[X Link](https://x.com/Prof_Dollar/status/2018057335806009741)  2026-02-01T20:22Z [----] followers, [---] engagements


"$PHAR Highlights clinical-stage pipeline including two key value-creating programs for primary immunodeficiencies with immune dysregulation and mtDNA-driven mitochondrial disease and introduces napazimone for the mitochondrial program. Investor day: https://www.pharming.com/nl/node/576 https://www.pharming.com/nl/node/576"  
[X Link](https://x.com/Prof_Dollar/status/2018567172973363356)  2026-02-03T06:08Z [----] followers, [---] engagements


"@BiotechAnalysst $QURE doesnt show its full hand on purpose. Silence weakness. Companies that need capital over-communicate. Fabry has strategic options and will be focused in time epilepsy is coming and Huntingtons will land with force. Preclinical work stays quiet until it matters. 🤝"  
[X Link](https://x.com/Prof_Dollar/status/2019871009835479419)  2026-02-06T20:29Z [----] followers, [----] engagements


"$QURE Playbook is clear: Bend the @FDA to reality. What just happened to $ATRA. 👇 FDA reversed years of prior alignment no safety issues GMP resolved - yet suddenly the trial design is no longer adequate. This isnt science. Its regulatory politics https://investors.atarabio.com/news-events/press-releases/detail/380/atara-biotherapeutics-provides-regulatory-and-business https://investors.atarabio.com/news-events/press-releases/detail/380/atara-biotherapeutics-provides-regulatory-and-business"  
[X Link](https://x.com/Prof_Dollar/status/2022419682901590298)  2026-02-13T21:16Z [----] followers, [----] engagements


"$QURE FWIW I see Vinay Prasad is back in the news again. I always warned that Vinay Prasad @VPrasadMDMPH was a terrible hire at the @FDA. Hes a Bernie Sanders puppet who allegedly terrorizes his staff and makes taxpayers pick up the tab for his cross country commutes. Its not too late https://t.co/5n22IVxPQC I see Vinay Prasad is back in the news again. I always warned that Vinay Prasad @VPrasadMDMPH was a terrible hire at the @FDA. Hes a Bernie Sanders puppet who allegedly terrorizes his staff and makes taxpayers pick up the tab for his cross country commutes. Its not too late"  
[X Link](https://x.com/Prof_Dollar/status/2022990450878292010)  2026-02-15T11:04Z [----] followers, [----] engagements


"$QURE just dropped Fabry 🔥 AMT-191 shows sustained supraphysiological -Gal A activity for [--] year stable lyso-Gb3 and more than 50% () of patients off ERT. Gene therapy doing what chronic infusions never could: functional cure. ✌ Full press release: https://www.uniqure.com/investors-media/press-releases https://www.uniqure.com/investors-media/press-releases"  
[X Link](https://x.com/Prof_Dollar/status/2019747047935537421)  2026-02-06T12:16Z [----] followers, [----] engagements


"While $SGMO is ahead in Fabry $QURE is the bigger strategic long-term winner. 😁 AMT-191 drives exceptionally high durable -Gal A expression fitting perfectly with Qures de-risked AAV platform & Huntinton's leadership. A powerfull portfolio amplifier not just a single asset $QURE only 50% off ERT and Grade3 #liver enzyme #elevations confirmed as dose-limiting #toxicity 😂 compare this to 100% of $SGMO patients off ERT for over [--] years and 100% clean safety $QURE only 50% off ERT and Grade3 #liver enzyme #elevations confirmed as dose-limiting #toxicity 😂 compare this to 100% of $SGMO patients"  
[X Link](https://x.com/Prof_Dollar/status/2019753069387329769)  2026-02-06T12:40Z [----] followers, [----] engagements


"RT @angie_rasmussen: Hey everyone I beg you to recall that this floppy haired dweeb who sucks at any job that doesnt involve contrarian po"  
[X Link](https://x.com/Prof_Dollar/status/2023368481245127018)  2026-02-16T12:06Z [----] followers, [---] engagements


"RT @davidaxelrod: And herein lies the problem"  
[X Link](https://x.com/Prof_Dollar/status/2023418404036866257)  2026-02-16T15:25Z [----] followers, [----] engagements


"@DesertDweller93 That valuation range feels like its just staking a claim on the floor with a + for safety 😉. $QURE s cash position isnt even factored in and the Epilepsy program could easily surpass Huntingtons in potential. The upside case writes itself. 💥"  
[X Link](https://x.com/Prof_Dollar/status/1977047412943237574)  2025-10-11T16:23Z [---] followers, [---] engagements


"@pawcio2009 @seedy19tron @A_May_MD Grateful to see $QURE lift me into the top [--] out of [---] () participants and [---] biotech picks 💪 A wonderful feeling after years of sharing insights on uniQure a nice bit of recognition and motivation to keep contributing. Follow along more to come"  
[X Link](https://x.com/Prof_Dollar/status/1977449473182928933)  2025-10-12T19:01Z [---] followers, [----] engagements


"@jlucer53 @canoebrookbl Honestly Im already surprised by the current valuation. Filing & approval still ahead the epilepsy program with its huge potential patient base not even priced in yet. Add their IP cash and other promising programs a 3x within [--] months wouldnt surprise me at all. $QURE"  
[X Link](https://x.com/Prof_Dollar/status/1977476057197584815)  2025-10-12T20:46Z [---] followers, [----] engagements


"Life hit you hard and you hit back harder. Scars become armor science your sword. Wishing you strength light and unstoppable fire on this next chapter. Lets go Nicole youve got this. 🔥🧬 Hey X and $QURE watchers give Nicole ❤❤👇 CEO of cancer gene therapy company: gets cancer🤯 Double mastectomy: ✅ Irony level: off the charts 📈 Fuel: science scars spite lets FUCKING go🔥 https://t.co/lvTcyd1dmo CEO of cancer gene therapy company: gets cancer🤯 Double mastectomy: ✅ Irony level: off the charts 📈 Fuel: science scars spite lets FUCKING go🔥 https://t.co/lvTcyd1dmo"  
[X Link](https://x.com/Prof_Dollar/status/1977772566434513268)  2025-10-13T16:24Z [---] followers, [----] engagements


"$QURE Matt Kapusta (CEO of uniQure) has been appointed to the Board of Directors of Decibel Therapeutics developer of cell-selective AAV gene therapies to restore and improve hearing and balance. $DBTX https://ir.decibeltx.com/news-releases/news-release-details/decibel-therapeutics-appoints-matthew-kapusta-its-board https://ir.decibeltx.com/news-releases/news-release-details/decibel-therapeutics-appoints-matthew-kapusta-its-board"  
[X Link](https://x.com/Prof_Dollar/status/1646554957334601728)  2023-04-13T16:44Z [----] followers, [---] engagements


"$QURE New target opportunity for @uniQure_NV Pharming has decided to terminate the licensing agreement with Orchard Therapeutics and discontinue the OTL-105 program and recently BioMarin discontiuned BMN [---] both are gene therapies for hereditary angioedema. $PHAR $ORTX $BMRN"  
[X Link](https://x.com/Prof_Dollar/status/1788185330274943033)  2024-05-08T12:33Z [----] followers, [----] engagements


"$PHAR "2025 total revenue guidance raised to US$325 - US$340 million". Further reports on first quarter [----] financial results and provides business update: https://www.pharming.com/news/pharming-group-reports-first-quarter-2025-financial-results https://www.pharming.com/news/pharming-group-reports-first-quarter-2025-financial-results"  
[X Link](https://x.com/Prof_Dollar/status/1920345252122021919)  2025-05-08T05:09Z [----] followers, [---] engagements


"@Kumodong_Li @ClearPath100 TNX for sharing Valuation remains hard to gauge: $QURE was once worth $4B with a weaker pipeline (more speculative) now barely $750M. 🤯 Back then Spark Therapeutics (ticker $ONCE ) was acquired for $5B making comparisons even more difficult. $5B now seems out of reach. ☹"  
[X Link](https://x.com/Prof_Dollar/status/1951458385171456326)  2025-08-02T01:41Z [----] followers, [---] engagements


"@appalachiangabe @TrueTrueIke While the market sleeps $QURE is quietly clearing the field. Remember $BLUE $ONCE and many others $SGMO could be next buried. With Huntingtons Epilepsy ALS & Fabry uniQure holds the most promising pipeline in gene therapy"  
[X Link](https://x.com/Prof_Dollar/status/1964331536838512718)  2025-09-06T14:15Z [----] followers, [----] engagements


"$PHAR Pharmings journey continues 🚀 FDA accepts & grants Priority Review for leniolisib in children (411) with APDS. If approved it will be the first treatment for these young patients 💜 Read more: https://www.pharming.com/news/pharming-group-announces-us-fda-acceptance-priority-review-supplemental-new-drug-application-leniolisib-pediatric-APDS https://www.pharming.com/news/pharming-group-announces-us-fda-acceptance-priority-review-supplemental-new-drug-application-leniolisib-pediatric-APDS"  
[X Link](https://x.com/Prof_Dollar/status/1973252964182855872)  2025-10-01T05:05Z [----] followers, [---] engagements


"@ZinselmeyerB Fair point. Early Fabry data is about signal not anecdotes. $QURE shows durable biology early while $SGMO debates timelines. Same pattern in epilepsy with a lead patient far ahead and STELLAR data. This is a platform being gift-wrapped for someone with a very big checkbook. 🚀"  
[X Link](https://x.com/Prof_Dollar/status/2019810390700622000)  2026-02-06T16:28Z [----] followers, [---] engagements


"$NAMS NewAmsterdam Pharma (with focus on cardiometabolic diseases) provides Corporate Update and 3Q23 Financial Highlights. BROADWAY Phase [--] trial enrollment completed; on-track to report topline data for Phase [--] BROOKLYN and BROADWAY trials in 2H [----]. https://ir.newamsterdampharma.com/news-releases/news-release-details/newamsterdam-pharma-provides-corporate-update-and-reports-third https://ir.newamsterdampharma.com/news-releases/news-release-details/newamsterdam-pharma-provides-corporate-update-and-reports-third"  
[X Link](https://x.com/Prof_Dollar/status/1724346825069461636)  2023-11-14T08:41Z [----] followers, [---] engagements


"$NAMS NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants https://ir.newamsterdampharma.com/news-releases/news-release-details/newamsterdam-pharma-announces-pricing-upsized-4165-million https://ir.newamsterdampharma.com/news-releases/news-release-details/newamsterdam-pharma-announces-pricing-upsized-4165-million"  
[X Link](https://x.com/Prof_Dollar/status/1867264896645357789)  2024-12-12T17:46Z [----] followers, [---] engagements


"$MRUS Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies https://ir.merus.nl/news-releases/news-release-details/lilly-and-merus-nv-announce-collaboration-discover-novel-t-cell https://ir.merus.nl/news-releases/news-release-details/lilly-and-merus-nv-announce-collaboration-discover-novel-t-cell"  
[X Link](https://x.com/Prof_Dollar/status/1351641228299919360)  2021-01-19T21:22Z [----] followers, [--] engagements


"$PHAR Pharming announces completion of enrollment in pediatric clinical trial of leniolisib marketed under the name #Joenja in the U.S. "This is the first clinical trial for younger pediatric patients (children aged [--] to [--] years) with APDS". Source: https://www.pharming.com/news/pharming-announces-completion-of-enrollment-pediatric-clinical-trial-leniolisib https://www.pharming.com/news/pharming-announces-completion-of-enrollment-pediatric-clinical-trial-leniolisib"  
[X Link](https://x.com/Prof_Dollar/status/1777225613784289514)  2024-04-08T06:43Z [----] followers, [---] engagements


"$PHAR Pharming announces the repurchase of outstanding [---] million convertible bonds due [----] https://www.pharming.com/news/pharming-group-announces-repurchase-outstanding-eu125-million-convertible-bonds-due-2025 https://www.pharming.com/news/pharming-group-announces-repurchase-outstanding-eu125-million-convertible-bonds-due-2025"  
[X Link](https://x.com/Prof_Dollar/status/1781366153354318081)  2024-04-19T16:56Z [----] followers, [---] engagements


"$CLPR $QURE partners in cure. Congratulations to our partner @uniQure_NV on the successful dosing of the first patient in the GenTLE Phase I/IIa clinical trial of AMT-260for the treatment of refractory mesial temporal lobe epilepsy (MTLE). #CLPT #genetherapy #epilepsy Congratulations to our partner @uniQure_NV on the successful dosing of the first patient in the GenTLE Phase I/IIa clinical trial of AMT-260for the treatment of refractory mesial temporal lobe epilepsy (MTLE). #CLPT #genetherapy #epilepsy"  
[X Link](https://x.com/Prof_Dollar/status/1859654889716293909)  2024-11-21T17:47Z [---] followers, [----] engagements


"$QURE Competitor stops commercialization of its hemophilia b gene therapy. Doctors said high cost logistical issues and the prospect of potential treatment advances were holding back the adoption. $PFE https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-says-it-will-end-global-development-gene-therapy-beqvez-nikkei-reports-2025-02-20/ https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-says-it-will-end-global-development-gene-therapy-beqvez-nikkei-reports-2025-02-20/"  
[X Link](https://x.com/Prof_Dollar/status/1892696727234179356)  2025-02-20T22:03Z [---] followers, [---] engagements


"@srqstockpicker Woahaha plot twist After $TRIL and $BLUE. Next in line is Hooters itself (to file for bankruptcy). 🙈 PS: Ladies are welcome to apply at $QURE. 🙊 https://www.newslooks.com/hooters-considers-bankruptcy-amid-falling-sales-and-debt-pressure/ https://www.newslooks.com/hooters-considers-bankruptcy-amid-falling-sales-and-debt-pressure/"  
[X Link](https://x.com/Prof_Dollar/status/1893373739049398545)  2025-02-22T18:54Z [---] followers, [---] engagements


"Deals like $GMAB and $MRUS (8B acquisition) make me believe even more that $QURE will be taken out and at an even higher price. Think double digits. 🚀 While big pharma faces expiring patents bioland is gaining huge momentum. https://ir.merus.nl/news-releases/news-release-details/genmab-acquire-merus-expanding-late-stage-pipeline-and https://ir.merus.nl/news-releases/news-release-details/genmab-acquire-merus-expanding-late-stage-pipeline-and"  
[X Link](https://x.com/Prof_Dollar/status/1972558860033699944)  2025-09-29T07:07Z [---] followers, [----] engagements


"@GeneInvesting Why is #RUCONEST missing a C1 esterase inhibitor recombinant indicated for the treatment of acute attacks in adult and adolescent patients with HAE More info: Company Pharming $PHAR reports (ongoing) strong growth in patients and prescribers. https://www.ruconest.com/ https://www.ruconest.com/"  
[X Link](https://x.com/Prof_Dollar/status/1973050585378091024)  2025-09-30T15:41Z [---] followers, [---] engagements


"@canoebrookbl Wouldnt surprise me if $AMGN ends up being the one. Strong fit with rare disease & gene therapy focus deep M&A pockets proven commercialization muscle for one-time treatments and a clear strategic need to expand in this space. Perfect match for $QURE s platform & pipeline"  
[X Link](https://x.com/Prof_Dollar/status/1977389298866352433)  2025-10-12T15:02Z [---] followers, [---] engagements


"$QURE uniQure believes that the FDA currently - NO - longer agrees that data from the Phase I/II studies of AMT-130 in comparison to an external control may be adequate to provide the primary evidence in support of a BLA submission. 😱😓💥 Source: https://www.uniqure.com/investors-media/press-releases https://www.uniqure.com/investors-media/press-releases"  
[X Link](https://x.com/Prof_Dollar/status/1985320562453778722)  2025-11-03T12:18Z [---] followers, [----] engagements


"@CuriousPawsCo A new trial basically means de-prioritization so option [--] = [--]. Think in terms of 7+ years; by then new technologies will dominate. Unrealistic path. Only real options are [--] or [--] or maybe 5: focus on EU/UK first. $QURE"  
[X Link](https://x.com/Prof_Dollar/status/1985445331543179427)  2025-11-03T20:33Z [---] followers, [---] engagements


"@Reinoud_Biotech @bio_clouseau Wouldnt surprise me if $QURE still applies for approval in 1Q26 but for now its about eliciting a reaction from the FDA. By going public before the FDA minutes uniQure shifted the spotlight. Its not just data being reviewed its the FDAs credibility on the line"  
[X Link](https://x.com/Prof_Dollar/status/1985454675110347066)  2025-11-03T21:10Z [---] followers, [---] engagements


"$QURE Dj vu Predefined statistical plan external control solid evidence yet rejection. This isnt an exception its a pattern. Politics at play not science. Shameful for patients and society alike $BHVN $BHVN rejection https://t.co/h0TFXkDyk1 $BHVN rejection https://t.co/h0TFXkDyk1"  
[X Link](https://x.com/Prof_Dollar/status/1985955269097017745)  2025-11-05T06:20Z [---] followers, [----] engagements


"Next Monday $QURE will host a webcast to announce 3Q2025 Financial Results on November [--] [----] at [----] a.m. ET. Webcast: https://www.globenewswire.com/Trackerdata=dDzecERPJrLR3OhZEcvx3KviMzl9KzPPhFMchgYW0sTMNRQbJ7nIstzjkbu1BvxM1Hls4aD2MNNEoy4HT2tgzCBGhIw7sFmB7pc7Q2O_NASm6lKmVVLrZfMn8bNcFvVxMXyDoU7AyMtULO9MjMVu79Xu5dEqSqNraOngEKMdW7H4PQBm-31HvTWn8Slk6X0Ztirph_pyIosGHmybq1nNLA=="  
[X Link](https://x.com/Prof_Dollar/status/1986406553667445122)  2025-11-06T12:13Z [---] followers, [----] engagements


"Huntingtons community is done waiting. 💥 This isnt about bad data its about a broken system Visit and join the movement for fairness progress hope. Together: strong informed united louder than ever Retweet #SpeakUp4HD #HD $QURE #genetherapy http://help4hd.org/speakup4hd http://help4hd.org/speakup4hd"  
[X Link](https://x.com/Prof_Dollar/status/1987235575774974213)  2025-11-08T19:07Z [---] followers, [----] engagements


"$QURE 3Q25 update. Quick: "plans to urgently interact with the FDA to define next steps" first cohort epilepsy finised and voluntarily paused enrollment in ALS study. Cash: $694.2 million sufficient into [----]. More: https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2025-financial-results-and https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2025-financial-results-and"  
[X Link](https://x.com/Prof_Dollar/status/1987856949342359593)  2025-11-10T12:16Z [---] followers, [----] engagements


"$QURE rises belief data and a touch of magic moving markets. For every #Huntington family that held faith through the silence your moment is coming. The awakening of gene therapys true promise. 🔥 #SpeakUp4HD #HD #genetherapy"  
[X Link](https://x.com/Prof_Dollar/status/1988338437498531868)  2025-11-11T20:09Z [---] followers, [----] engagements


"The HD community is rising and you can help. Signing the petition is free fast and powerful. 💜 AMT-130 of $QURE is the first therapy to ever slow Huntingtons but FDA delays mean families wait while time slips away. 👉 Now: 👉 Retweet and like. 😊🙏 https://c.org/QZcHFyXKH7 https://c.org/QZcHFyXKH7"  
[X Link](https://x.com/Prof_Dollar/status/1989337695919702359)  2025-11-14T14:20Z [---] followers, [----] engagements


"Challenge time #SpeakUp4HD needs your spark. 👉 Tag [--] global celeb + [--] friend. ✍ Sign & share the petition: 💜 Lets push Huntington families into the spotlight they deserve. #HuntingtonsDisease $QURE #AMT130 Ill start: @chrishemsworth @floszcrxl https://c.org/Srtps5vX2j https://c.org/Srtps5vX2j"  
[X Link](https://x.com/Prof_Dollar/status/1989794997156401343)  2025-11-15T20:37Z [---] followers, [----] engagements


"7500+ signatures reached thank you truly. 🙏 Your voices are fueling real momentum. But this fight isnt won yet. Stand with us: sign share retweet. ✍ #SpeakUp4HD $QURE #HuntingtonsDisease https://c.org/Srtps5vX2j https://c.org/Srtps5vX2j"  
[X Link](https://x.com/Prof_Dollar/status/1990095713145930061)  2025-11-16T16:32Z [---] followers, 13.2K engagements


"Boom 10000+ signatures 💜 Thank you truly deeply. A reminder to the @FDA that hope doesnt pause for bureaucracy. Lets make this the Christmas where patients finally get the response they deserve. 🎄✨ ✍ #SpeakUp4HD $QURE #HuntingtonsDisease http://c.org/Srtps5vX2j 7500+ signatures reached thank you truly. 🙏 Your voices are fueling real momentum. But this fight isnt won yet. Stand with us: sign share retweet. ✍ https://t.co/roG8Irgtq8 #SpeakUp4HD $QURE #HuntingtonsDisease https://t.co/ZnBcbeWtRL http://c.org/Srtps5vX2j 7500+ signatures reached thank you truly. 🙏 Your voices are fueling real"  
[X Link](https://x.com/Prof_Dollar/status/1990403142706422249)  2025-11-17T12:54Z [----] followers, [----] engagements


"@A_May_MD Thank you for your incredibly thorough analysis on $QURE - truly impressive work. Your time insight and effort help lift the whole community. Grateful youre here and grateful youre willing to share it with all of us. 🙏"  
[X Link](https://x.com/Prof_Dollar/status/1990464423501463908)  2025-11-17T16:57Z [---] followers, [---] engagements


"@SweeperPod Surinames chances improved mainly because Mexico U.S.A. & Canada are already qualified as hosts and dont compete in the qualifiers. On top of that the expanded World Cup format gives more teams a realistic path to qualify. Like Curaao you're welcome anyway. #WCQ #WCQ2026"  
[X Link](https://x.com/Prof_Dollar/status/1990539605951853023)  2025-11-17T21:56Z [---] followers, [----] engagements


"@DrMakaryFDA If your guidance needs a clarification about the clarification somethings broken. Sponsors and families fighting deadly diseases deserve crystal-clear consistent communication on day one. Not a maze of follow-up fixes. $QURE ✌"  
[X Link](https://x.com/Prof_Dollar/status/1991259490075787318)  2025-11-19T21:37Z [----] followers, [----] engagements


"🚨 When biotech warns that FDA unpredictability is driving lifesaving innovation out of the U.S. something is deeply wrong. This moment calls for presidential backbone: clean house cut chaos protect rare-disease innovation. Act. Now. $QURE $CLPT $SRPT https://www.youtube.com/watchv=HBMNxLC8NlM https://www.youtube.com/watchv=HBMNxLC8NlM"  
[X Link](https://x.com/Prof_Dollar/status/1991875421898740224)  2025-11-21T14:24Z [----] followers, [----] engagements


"No shifting goalposts AMT-130 deserves the fair science-driven FDA review it was promised. $QURE has been FIRST at every step and ALWAYS patient-first. Now the HD community rises. For truth. For science. For their future. Raise your voice and join 👉 https://www.votervoice.net/iframes/HDSA/Campaigns/131691/Respond https://www.votervoice.net/iframes/HDSA/Campaigns/131691/Respond"  
[X Link](https://x.com/Prof_Dollar/status/1992291079249383811)  2025-11-22T17:56Z [----] followers, [----] engagements


"@uniQure_NV Strong work But $QURE is now the Huntington company previously the Hemophilia company. If it wants to be a true platform play it must deliver on HD push real progress in epilepsy shut down ALS and launch a new program built on its own platform strengths. [----] outlook soon"  
[X Link](https://x.com/Prof_Dollar/status/1993406247081853299)  2025-11-25T19:47Z [----] followers, [----] engagements


"🎥 $QURE Unpacking the #Huntington topline results: what the data really says what it means for patients and where the field is heading. Must-watch for anyone following #AMT130 gene therapy or the future of this disease. #SpeakUp4HD #HDCommunity $CLPT https://www.youtube.com/watchv=wKj1JRfJBRE https://www.youtube.com/watchv=wKj1JRfJBRE"  
[X Link](https://x.com/Prof_Dollar/status/1993733504404701545)  2025-11-26T17:28Z [----] followers, [----] engagements


"$QURE listed among the most oversold biotech stocks yet its story is anything but weak. William Blair highlights strong #AMT130 data rising patient demand and mounting pressure from the medical community for a fast fair FDA path. 🎥 Video: #SpeakUp4HD https://finance.yahoo.com/news/william-blair-maintains-market-perform-133911290.html https://finance.yahoo.com/news/william-blair-maintains-market-perform-133911290.html"  
[X Link](https://x.com/Prof_Dollar/status/1994094601456767125)  2025-11-27T17:22Z [----] followers, [----] engagements


"@shitcoSavant The real issue isnt $QURE. Its what this means for patients. For #Huntingtons patients and families way more lives will be lost by blocking safe innovation than by allowing it. This is what happens when the @FDA forgets who its supposed to protect. #SpeakUp4HD #AMT130 $CLPT"  
[X Link](https://x.com/Prof_Dollar/status/1995128546079998284)  2025-11-30T13:51Z [----] followers, [----] engagements


"$QURE Dont expect an update on #AMT130 until theres new perspective. Current argument only gets stronger with Pazdurs departure. FDA is just zigzagging downhill every process a mess. Couldnt ask for a better sign of uncertainty. At best well see an R&D update: new program"  
[X Link](https://x.com/Prof_Dollar/status/1995947400016589219)  2025-12-02T20:05Z [----] followers, [----] engagements


"$QURE When regulators abandon evidence they abandon patients. Gene therapy and #Huntingtons is NO exception [--] former FDA commissioners now warn that the agencys recent moves threaten the very model meant to safeguard safety effectiveness and progress. #SpeakUp4HD #AMT130 In a remarkable perspective piece just published in the New England Journal of Medicine nearly every living FDA Commissioner or Acting Commissioner blast Vinay Prasad's recent memo to CBER staff outlining changes to vaccine policy. *Extremely* uncommon https://t.co/wjiqikalmK In a remarkable perspective piece just published"  
[X Link](https://x.com/Prof_Dollar/status/1996360128661176774)  2025-12-03T23:25Z [----] followers, [----] engagements


"Deeply disappointing Not just for $QURE but for every HD family fighting for time. The data are real the need is urgent and the community has spoken louder than ever. Push full-speed toward the EU and leadership beyond the FDA. Patients deserve better. https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease-1 https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease-1"  
[X Link](https://x.com/Prof_Dollar/status/1996554908536074556)  2025-12-04T12:19Z [----] followers, 29.5K engagements


"Upside: Focus is on data not the method not the science. FDA is keeping door open. It's a regulatory hurdle not a scientific rejection. #AMT130 remains milestone in brain gene therapy with strong safety profile. $QURE Y2026: More data follow-ups and a fresh BLA path ahead.💙 Deeply disappointing Not just for $QURE but for every HD family fighting for time. The data are real the need is urgent and the community has spoken louder than ever. Push full-speed toward the EU and leadership beyond the FDA. Patients deserve better. https://t.co/vzi7EJC8Qo https://t.co/x9LDxGSvWC Deeply disappointing"  
[X Link](https://x.com/Prof_Dollar/status/1996638014039380435)  2025-12-04T17:49Z [----] followers, [----] engagements


"@RNAiAnalyst Now time has to do its work for $QURE. Hopefully they captured every parameter even the ones that once seemed irrelevant. Shall we agree to meet again next year same place same time Around mid-September https://x.com/Prof_Dollar/status/1996638014039380435 Upside: Focus is on data not the method not the science. FDA is keeping door open. It's a regulatory hurdle not a scientific rejection. #AMT130 remains milestone in brain gene therapy with strong safety profile. $QURE Y2026: More data follow-ups and a fresh BLA path ahead.💙 https://x.com/Prof_Dollar/status/1996638014039380435"  
[X Link](https://x.com/Prof_Dollar/status/1996905688053043364)  2025-12-05T11:33Z [----] followers, [---] engagements


"@DrMakaryFDA Encouraging words from @DrMakaryFDA today. If real-world data can and should be part of FDA decision-making and companies must have a path to present it that opens new perspective. Also for #AMT130 where some data spans different eras but real-world impact is undeniable. $QURE"  
[X Link](https://x.com/Prof_Dollar/status/2001017151805854128)  2025-12-16T19:50Z [----] followers, [---] engagements


"@DrMakaryFDA Some blind spots: ❌ No consistency in accelerated approval ❌ No accountability for reversals that cost lives ❌ No urgency for patients with fatal diseases like HD A new era of innovation isnt measured by checkmark but by outcomes for patients still waiting. $QURE $CLPT"  
[X Link](https://x.com/Prof_Dollar/status/2002036917966413853)  2025-12-19T15:22Z [----] followers, [----] engagements


"🚨 Jaw-dropping. This is what $QURE and HD families are up against: FDA dysfunction hurting those who cant afford delays. Brilliant reporting @By_CJewett. Keep the pressure on. 👍 Like follow retweet. #SpeakUp4HD #AMT130 NEW: Last month RFK Jr.'s dep. sec. staged something of a coup against FDA boss Marty Makary. The White House waved it off. But what a year: [----] FDA staff out a drop in foreign inspections and $$ restrictions that left lab staff sitting idle. GIFT: https://t.co/cg7HyOcpqd NEW: Last month RFK Jr.'s dep. sec. staged something of a coup against FDA boss Marty Makary. The White"  
[X Link](https://x.com/Prof_Dollar/status/2002524089966329926)  2025-12-20T23:38Z [----] followers, [----] engagements


"$QURE From Fast Track (2019) RMAT (2024) FDA alignment on Accelerated Approval (Dec 24) Breakthrough Therapy (Apr 25) positive topline data the path for #AMT130 was built step by step WITH @FDA involvement at EVERY stage Regulatory whiplash #huntingtonsdisease"  
[X Link](https://x.com/Prof_Dollar/status/2003181252074168491)  2025-12-22T19:10Z [----] followers, [----] engagements


"Add: uniQure. Born as Amsterdam Molecular Therapeutics world-class gene therapy leader first gene therapy approved in the West pioneering AAV platform & driving breakthroughs in #Huntingtons #Epilepsy #Hemophilia #ALS & more. 🔬 A Dutch biotech legacy in the making. $QURE Dutch inventions [--]. Microscope (1590)  [--]. Telescope (1608)  [--]. Artificial Kidney (1943)  [--]. Heart-Lung Machine (1953)  [--]. Pendulum Clock (1656)  [--]. Fahrenheit (1724)  [--]. CD (1979)  [--]. DVD (1995)  [--]. Wi-Fi Standards (1990s)  [--]. Dutch inventions [--]. Microscope (1590)  [--]. Telescope (1608)  [--]. Artificial Kidney (1943)  4."  
[X Link](https://x.com/Prof_Dollar/status/2003569084664004739)  2025-12-23T20:51Z [----] followers, [----] engagements


"@DesertDweller93 Interesting breakdown. One question I keep coming back to: the [--] sham patients who never crossed over. Are they still being followed long-term Their trajectories could be incredibly valuable as extended comparison data. Any insights on whether theyre still part of the study"  
[X Link](https://x.com/Prof_Dollar/status/2003571190418538969)  2025-12-23T20:59Z [----] followers, [---] engagements


"@AB1001_disciple @DesertDweller93 Fair point but there is added value. The Enroll-HD natural history data was collected with older tools older imaging standards older scoring methods. These [--] are measured with todays tech and todays consistency. Thats a different level of signal quality. $QURE"  
[X Link](https://x.com/Prof_Dollar/status/2003577141259366731)  2025-12-23T21:23Z [----] followers, [---] engagements


"@DesertDweller93 After receipt of AMT-130 is the key phrase but the [--] sham patients never received it. If theyre no longer alive that contrast could speak volumes about disease trajectory. Just saying: in #Huntingtons every data point matters. Sometimes absence of data is data. $QURE"  
[X Link](https://x.com/Prof_Dollar/status/2003584622874214401)  2025-12-23T21:52Z [----] followers, [---] engagements


"Watched Prof. Aswath Damodarans masterclass on valuation highly recommended $QURE sits in that middle young growth space: the narrative side has huge potential. Maybe a new CEO could deliver that story more convincingly. Great insights on how narrative + numbers must align. The godfather of valuation dropped a 30-minute investing masterclass https://t.co/tixBx170EI The godfather of valuation dropped a 30-minute investing masterclass https://t.co/tixBx170EI"  
[X Link](https://x.com/Prof_Dollar/status/2003972084108873963)  2025-12-24T23:32Z [----] followers, [----] engagements


"To all serious $XBI biotech and medtech investors: get in on this Join for free share your insights and learn from the brilliant variety of picks rolling in. #Biopick2026 is where the smartest minds come to play. Dont miss your chance to be part of it. 🚀📈 There are a couple of early favorites emerging for most picked in biosquidgames [----] but its not a ridiculous amount. The variety of picks has been impressive so far. Looks like investors learned from previous years. Reminder deadline is midnight 2-Jan-26 (Friday). #Biopick2026 There are a couple of early favorites emerging for most picked"  
[X Link](https://x.com/Prof_Dollar/status/2004672310784262148)  2025-12-26T21:54Z [----] followers, [---] engagements


"@doepke_michel My top [--] biotech / $XBI M&A list into [----] $QURE $AMGN ( $10B )"  
[X Link](https://x.com/Prof_Dollar/status/2005371592176791709)  2025-12-28T20:13Z [----] followers, [----] engagements


"✨ Once $QURE magically pulled a rabbit out of the hat with its Hemophilia B gene therapy. Now the biotech is cooking up an upgraded #Huntingtons program too. Will AMT-130 be the next trick 🧬🎩 Only once the current act gets the stamp of approval but the anticipation is real uniQures next generation HD gene therapy targeting HTT HTT1a and MSH3 (somatic instability). One and only so far. Once in clinical trial every competitor will hate them Abstract from ASGCT annual meeting. https://t.co/ydBfsHQHg9 uniQures next generation HD gene therapy targeting HTT HTT1a and MSH3 (somatic instability)."  
[X Link](https://x.com/Prof_Dollar/status/2006000404312768620)  2025-12-30T13:52Z [----] followers, [----] engagements


"@pawcio2009 @3IDWarrant Congrats to @3IDWarrant on winning the final #biopick2025 award 🎉 Incredible call on $ARWR coming within 2% of your EOY target is seriously impressive. Well deserved Chris. Enjoy that extra [----] pick 👏"  
[X Link](https://x.com/Prof_Dollar/status/2006525651222933881)  2026-01-01T00:39Z [----] followers, [---] engagements


"@pawcio2009 @A_May_MD 2nd place in #Biopick2025 goes to @A_May_MD 🥈 Picking $RGLS and getting a buyout along the way thats how you play the game. Strong call Adam. Respect. 👊👏"  
[X Link](https://x.com/Prof_Dollar/status/2006526862810640655)  2026-01-01T00:44Z [----] followers, [---] engagements


"From ASMLs insane machines powering the worlds most advanced chips to $QURE s gene therapies pushing the frontier of medicine. Different fields same DNA: precision patience world-class impact. Small country. Outsized impact. Never bet against Dutch deep tech. 👊🚀 The Ridiculous Engineering Of The World's Most Important Machine https://t.co/NzVizid9Dq The Ridiculous Engineering Of The World's Most Important Machine https://t.co/NzVizid9Dq"  
[X Link](https://x.com/Prof_Dollar/status/2006834124175331383)  2026-01-01T21:05Z [----] followers, [---] engagements


"$QURE It's a sign. ✌😉 This is over [---] years old btw https://t.co/v33XGftzAD This is over [---] years old btw https://t.co/v33XGftzAD"  
[X Link](https://x.com/Prof_Dollar/status/2007199344345395439)  2026-01-02T21:16Z [----] followers, [----] engagements


"@pawcio2009 Once in a generation a stock is destined for greatness. $QURE carries that spark. Gene therapy where others stopped #Huntingtons disease where it truly matters. Congratulations in advance This is how Dutch giants are forged. Top-10 destiny in #biopick2026. +100% is the floor"  
[X Link](https://x.com/Prof_Dollar/status/2007539091160600697)  2026-01-03T19:46Z [----] followers, [----] engagements


"@biopharmacaster @pawcio2009 Investors understand dilution timelines & asymmetric upside. Gamblers chase candles. With entrepreneurship on one side and an FDA narrative that will turn the runway matters more than the entry point. $QURE builds assets that end in strategic hands - at an acquisition premium"  
[X Link](https://x.com/Prof_Dollar/status/2007543161229586444)  2026-01-03T20:02Z [----] followers, [---] engagements


"@pawcio2009 How did I get to $104.04 for $QURE Simple math. Last year I called $52.02 the mirror of year [----]. After the FDA stumble I doubled down. Same math stronger conviction. $52.02 [--]. 👌😊 Sometimes chaos sharpens the signal. $XBI"  
[X Link](https://x.com/Prof_Dollar/status/2007563198879203731)  2026-01-03T21:22Z [----] followers, [----] engagements


"@Biotech_AI @pawcio2009 Because FDA comment was regulatory not scientific. Data didnt fail the bar moved. $QURE holds strong safety data valuable IP AMT-130 long-term upside an epilepsy program and multiple strategic paths. Best case 2026: renewed FDA alignment EU momentum and acquisition. 🚀"  
[X Link](https://x.com/Prof_Dollar/status/2007784675931312493)  2026-01-04T12:02Z [----] followers, [---] engagements


"@Denizt89 @Biotech_AI @pawcio2009 EU progress now depends on uniQure stepping up. Were waiting for action and clarity via a press release or the 4Q25 update in February. Same data different regulators. EMA and the UKs MHRA may prove more pragmatic than the @FDA. Time for $QURE to move"  
[X Link](https://x.com/Prof_Dollar/status/2007942854123909617)  2026-01-04T22:30Z [----] followers, [---] engagements


"Are you active on #LinkedIn Read it. Support it. Share it. Bring your network into the conversation. Awareness matters momentum matters and Huntington's patients and families are watching. Lets amplify this together. #HuntingtonsDisease #HDCommunity #AMT130 #raredisease $QURE Great article by Christy Dearien - Hope on hold: FDA decision will have detrimental impact on families with Huntingtons disease "Our loved ones deserve better." @FDACBER @fdacder @FDACDERDirector @canoebrookbl @DesertDweller93 https://t.co/EQrpGQe4Bg Great article by Christy Dearien - Hope on hold: FDA decision will have"  
[X Link](https://x.com/Prof_Dollar/status/2008649908526645440)  2026-01-06T21:20Z [----] followers, [---] engagements


"@pawcio2009 Every curse has its exception. In a sea of fallen picks $QURE stands untouched. $XBI The [--] who chose it didnt follow the game they read the future. Quarians arent made by crowds. Theyre made by conviction. 🔥"  
[X Link](https://x.com/Prof_Dollar/status/2009911851966984535)  2026-01-10T08:55Z [----] followers, [----] engagements


"@DesertDweller93 Key milestone is BLA acceptance in 1Q or later with added data. After years of FDA alignment acceptance is already half an approval. Once that door opens commercialization plans move forward and the pipeline keeps advancing. With or without FDA turbulence $QURE stands strong"  
[X Link](https://x.com/Prof_Dollar/status/2010014730883395841)  2026-01-10T15:43Z [----] followers, [---] engagements


"$QURE sharpened pipeline. AMT-240 (Alzheimers) deprioritized; AMT-162 (ALS) likely next. Focus shifts to Epilepsy & Fabry both with new data. No new AMT-130 data and no INDs planned for [----]. After renewed FDA alignment and no new trial the endgame is clear: strategic sale. 🔥"  
[X Link](https://x.com/Prof_Dollar/status/2011153476173382093)  2026-01-13T19:08Z [----] followers, [----] engagements


"@DesertDweller93 Clear cadence ahead the year 2026: 1Q Fabry. 2Q Epilepsy. 3Q Huntingtons. 4Q Acquisition. Safety gates value inflection then strategy. $QURE isnt drifting its executing a timeline. Patience rewards those who can stay calm while others rush"  
[X Link](https://x.com/Prof_Dollar/status/2011165546612736266)  2026-01-13T19:56Z [----] followers, [---] engagements


"@pawcio2009 @AlexiLalas Haha. Top [--]. Sure. ✌😎"  
[X Link](https://x.com/Prof_Dollar/status/2011168699135218092)  2026-01-13T20:09Z [----] followers, [---] engagements


"@unknown_tester_ @DesertDweller93 No such thing as a silly question 😊 I think extra data (more patients over a certain period) and analysis will be necessary. That should be available by then if it can be done without an additional study. $QURE"  
[X Link](https://x.com/Prof_Dollar/status/2011178531435270366)  2026-01-13T20:48Z [----] followers, [---] engagements


"@ghill37g @DesertDweller93 FDA decisions played a role. Also other GT companies dropped. $QURE may have already shared some [----] outlook with insiders; pipeline hasnt expanded they have plenty of cash. Hopefully not for an extra study would take too long. Patience might be wiser focusing on pipeline"  
[X Link](https://x.com/Prof_Dollar/status/2011180367999324438)  2026-01-13T20:55Z [----] followers, [---] engagements


"@4drant [--] of [--] - Where the $QURE analysis overreaches 👇 The idea that FDA will force a new randomized sham-controlled trial in Huntingtons is unlikely. Ethically fraught slow and value-destructive. @FDA generally seeks pragmatic paths in fatal CNS diseases not academic perfection"  
[X Link](https://x.com/Prof_Dollar/status/2012247587059913131)  2026-01-16T19:36Z [----] followers, [---] engagements


"@4drant @FDA [--] of [--] More realistic outcomes for $QURE: BLA with restricted label Conditional/Accelerated Approval based on biomarkers Extended post-marketing commitments Additional longitudinal data not a brand-new trial Binary thinking misses FDA reality"  
[X Link](https://x.com/Prof_Dollar/status/2012247680357933537)  2026-01-16T19:36Z [----] followers, [---] engagements


"@4drant @FDA [--] of [--] The massive secondary offering narrative also doesnt fit. $QURE has runway. A BLA acceptance increases strategic optionality not dilution pressure. Big Pharma prefers M&A premiums over funding endless trials"  
[X Link](https://x.com/Prof_Dollar/status/2012247833970180245)  2026-01-16T19:37Z [----] followers, [---] engagements


"@4drant @FDA [--] of [--] What the analysis misses entirely: FDA itself built expectations. Fast Track. RMAT. Breakthrough Therapy. Prior alignment. That creates regulatory reliance. FDA cant suddenly treat $QURE's AMT-130 as a random Phase I/II asset"  
[X Link](https://x.com/Prof_Dollar/status/2012247938072809885)  2026-01-16T19:37Z [----] followers, [---] engagements


"@4drant @FDA [--] of [--] And most importantly: this is not a single-asset story. $QURE owns a CNS gene therapy platform: Surgical AAV delivery Epilepsy Fabry Deep IP #AMT130 is the spearhead not the whole army"  
[X Link](https://x.com/Prof_Dollar/status/2012248052715655236)  2026-01-16T19:38Z [----] followers, [---] engagements


"@4drant @FDA [--] of [--] Bottom line: Clinical claims may have been oversold. Biology remains intact. @FDA is strict not hostile. Endgame isnt statistical purity its strategic value. Biology bureaucracy. Just never in a straight line. $QURE"  
[X Link](https://x.com/Prof_Dollar/status/2012248189085061309)  2026-01-16T19:38Z [----] followers, [---] engagements


"@4drant @FDA [--] of (another) [--] 😊 Youre broadly right but a few points need tightening for accuracy: $QURE study was not powered to show statistical superiority vs the sham group. The sham arm was small (n10) and intended for internal context not as a registrational primary comparator"  
[X Link](https://x.com/Prof_Dollar/status/2012485591624003940)  2026-01-17T11:22Z [----] followers, [---] engagements


"@4drant @FDA [--] of [--] $QURE did not pick a new control arbitrarily. Enroll-HD was pre-specified as supportive/external context but it became more prominent after sham group proved unusually stable. You can slice brains in animals in humans you cant. Thats why biomarkers like NfL matter"  
[X Link](https://x.com/Prof_Dollar/status/2012485925977067567)  2026-01-17T11:23Z [----] followers, [---] engagements


"@4drant @FDA [--] of [--] Neurofilament light (NfL) is objective biologically meaningful and cannot be placebod. Its improvement strongly supports disease modification even if its not the primary endpoint"  
[X Link](https://x.com/Prof_Dollar/status/2012486071448146385)  2026-01-17T11:24Z [----] followers, [--] engagements


"@4drant @FDA [--] of [--] A compromise path (biomarker-driven accelerated approval + follow-up obligations) for $QURE and @FDA is therefore plausible. Not guaranteed but reasonable"  
[X Link](https://x.com/Prof_Dollar/status/2012486212137767295)  2026-01-17T11:24Z [----] followers, [---] engagements


"@canoebrookbl @peter_mantas A 3-year placebo Good luck enrolling No #huntingtons patient will volunteer for sham surgery while alternatives emerge. You dont gamble your last lifeline on trial design theater. AA first real-world confirmation second thats how you serve patients and science. $QURE @FDA"  
[X Link](https://x.com/Prof_Dollar/status/2012519703625785616)  2026-01-17T13:37Z [----] followers, [---] engagements


"@johnkmason @4drant @FDA Youre missing the key fact: sham control existed only at [--] year. There is no sham comparison at 3Y or 4Y your argument doesnt hold. Long-term data are about durability not a control arm that no longer exists. Using we wont cover your missing dossier knowledge AI or not. 🎯"  
[X Link](https://x.com/Prof_Dollar/status/2014567778682818807)  2026-01-23T05:16Z [----] followers, [--] engagements


"@BentheFidler Partnership between $SHPG (Shire) & $QURE in the making Your opinion: @DrMedicalValue @psuvafan007 @srqstockpicker @jimcramer"  
[X Link](https://x.com/Prof_Dollar/status/639074429084041216)  2015-09-02T13:56Z [----] followers, [--] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing